Search

everythinglearnresearchcommunity

for

Search:↓

The report recommends personalized treatment for women's sexual dysfunctions and more research on effective therapies.

Telogen effluvium is a reversible hair loss condition that requires a detailed diagnosis and often resolves on its own.

Lifestyle changes can improve body composition, excess male hormone levels, and insulin resistance in women with PCOS.

Current treatments for alopecia show no significant long-term benefits.

Alopecia areata causes hair loss, has no cure, and various treatments exist.

Telogen effluvium is a common type of hair loss that can resolve on its own or become chronic, with treatment depending on early diagnosis.

Surgeons must understand the full care process for gender confirmation surgery to help transgender individuals effectively.

Finasteride and minoxidil are effective for hair regrowth, while treatments for alopecia areata have varying success and continuous treatment is necessary.

Hair loss in men treated best with early medication or transplant, new treatments researched.

Hair follicles are hormone-sensitive and involved in growth and other functions, with potential for new treatments, but more research is needed.

Treatments for permanent hair loss from scarring aim to stop further loss, not regrow hair, and vary by condition, with partial success common.

Hair loss that spreads out can often fix itself or be treated by finding and handling the cause.

New treatments for male hypogonadism are effective and should be personalized.

Androgenetic alopecia involves genetics, hormones, and can be treated with medications or surgery.

Hormones, especially androgens, play a key role in acne, which can be a symptom of systemic diseases like PCOS and may require targeted treatment.

Some treatments, like corticosteroids and sensitizing agents, can help with alopecia areata, but more high-quality research is needed.

Chronic Telogen Effluvium may resolve after years and is diagnosed by examining the patient's history and clinical signs, with treatment aimed at underlying causes and possibly minoxidil.

There is no clear recommendation for using selenium in cancer patients; it may be beneficial to correct low selenium levels before treatment.

SHBG may be a useful early indicator and treatment target for PCOS.

The document concludes that while there are various treatments for Alopecia Areata, there is no cure, and individualized treatment plans are essential due to varying effectiveness.

Hair loss in women may have causes other than hormones.

Hair follicles offer promising targets for delivering drugs to treat hair and skin conditions.

Some cats with sudden hair loss and tiredness might have cancer-related alopecia.

A new mutation in the STING protein causes a range of symptoms and its severity may be affected by other genetic variations; treatment with a specific inhibitor showed improvement in one patient.

LGBT individuals have unique skin health needs, including higher STD risks and side effects from gender-affirming treatments, requiring dermatologists to offer knowledgeable and culturally competent care.

Hormones might affect the skin condition hidradenitis suppurativa, but their exact role is unclear.

Menopause significantly reduces skin collagen, leading to thinner, less elastic skin, and hormone replacement may help but requires careful consideration.

Hidradenitis suppurativa may be related to hormones and patients often have metabolic disorders; more research is needed to understand this connection.

Young women with diffuse hair loss may have low SHBG levels, which could lead to more active testosterone and contribute to their hair loss.

The document concludes that treatment for cutaneous T-cell lymphoma should be customized to each patient's disease stage, balancing benefits and side effects, with no cure but many patients living long lives.